Antibiotic resistance - The faceless threat

International Journal of Risk and Safety in Medicine

Volumn 17, Issue 3-4, 2005, Pages 103-110

  Cars, Otto ^a   Nordberg, Per ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COLISTIN; GLYCOPEPTIDE; METICILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; DISEASE TRANSMISSION; DRUG COST; ECOLOGY; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE NEED; HUMAN; MORTALITY; NONHUMAN; REVIEW; SIDE EFFECT; THREAT; TOXICITY;

EID: 27744600034     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. F.F. Barrett, R.F. McGehee and M. Finland, Methicillin-resistant Staphylococcus aureus at Boston City hospital, N. Engl. J. Med. 279 (1968), 441.
2. O. Cars, S. Mölstad and A. Melander, Variation in antibiotic use in the European Union, Lancet 357 (2001), 1851-1853.
3. M.L. Cohen, Epidemiology of drug resistance: Implications for a post-antimicrobial era, Science 257 (1992), 1050-1055.
4. S.E. Cosgrove, E.N. Sakoulas, M.J. Schwaber, Karchmer and Y. Carmeli, Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis, Clin. Infect. Dis. 36 (2003), 53-59.
5. F. Fasehun, The antibacterial paradox: essential drugs, effectiveness, and cost, Bull. World Health Organ. 3 (1999), 211-216.
6. Health Protection Agency, UK, Staphylococcus aureus bacteraemia laboratory reports and methicillin susceptibility: England and Wales 1992-2002. http://www.hps.org.uk/infections/topics_az/staphylo/lab_data_staphyl.htm, accessed 30 June 2004.
7. M.H. Kollef, G. Sherman, S. Ward and V.J. Fraser, Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients, Chest 2 (1999), 462-474.
8. J. Okumura, K. Osaka and N. Okabe, Widespread multi-antimicrobial- resistant shigella in Asia: What does it mean? Abstract No. AM 011, International Conference on Improving Use of Medicines, 2004.
9. D. Paterson and L.B. Rice, Empirical antibiotic choice for the seriously ill patients: Are minimization of selection resistant organisms and maximization of individual outcome mutually exclusive?, Clinical Infectious Diseases 36 (2003), 1006-1012.
10. A. Radyowijati and H. Haak, Determinants of antimicrobial use in the developing world, USAID, Bureau of Global Health, The Child Health Research Project Special Report, 2002.
11. R. Smith, R. Beaglehole, D. Woodward and N. Drager, Global Public Goods for Health, Oxford University Press, 2003.
12. R.D. Smith and J. Coast, Antimicrobial resistance: a global response, Bulletin of the World Health Organisation 80 (2002), 126-133.
13. K. Stöhr, Problems from antimicrobial use in farming, Essential Drug Monitor. 28-29 (2000), 10-11.
14. J. Turnidge, Impact of antibiotic resistance on the treatment of sepsis, Scandinavian Journal of Infectious Diseases 35 (2003), 677-682.
15. M. Whitby, M.L. McLaws and G. Berry, Risk of death from methicillin-resistant Staphylococcus aureus bacteremia: a meta-analysis, Med. J. Austr. 5 (2002), 264-267.
16. WHO-EMRO, 2002. Agenda item 11(a): Antimicrobial resistance and rational use of Antimicrobial agents, WHO website: www.int/medicines/organization/par/ cd_25th_anniversary/4-rational/amr.ppt. Accessed August 18th 2003, 49th Session of the Regional Committee for the Eastern Mediterranean; 30 September-3 October 2002, Cairo, Egypt. Accessed 30 June 2004.
17. WHO fact sheet on Antimicrobial resistance, 2002. http://www.who.int/ mediacentre/factsheets/fs194/en/print.html, accessed 30 June 2004.
18. WHO, Shaping the future, World Health Report, 2003.
19. WHO, WHO global strategy for containment of antimicrobial resistance, WHO/CDC/CSR/DRS/2001.2, Geneva, 2001.
20. R. Wise, T. Hart and O. Cars, Antimicrobial resistance is a major threat to public health, BMJ 317 (1998), 609-610.